• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Agro Capital Management Corp
Currenc Group Inc. - Ordinary Shares
DeFi Technologies Inc
Ecolomondo Corp
M.D. Sass Concentrated Value ETF
Materialise NV - American Depositary Shares
VegaShares AI Thermal, Cooling & Power Management ETF
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

9.740 -0.380 (-3.75%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 885,434
Open 10.18
Bid (Size) 9.700 (100)
Ask (Size) 10.20 (100)
Prev. Close 10.12
Today's Range 9.705 - 10.23
52wk Range 8.943 - 25.77
Shares Outstanding 49,383,711
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study ↗
October 06, 2026
Monte Rosa Therapeutics (NASDAQ:GLUE) reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The... 
Via MarketBeat
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 62.2% below 52-week high
9.740
8.9452W Low 25.7752W High
1 Week 8.4% below 1-week high
9.711W Low 10.631W High

Monte Rosa Therapeutics, Inc. - Common Stock (GLUE) traded between $8.94 and $25.77 over the past 52 weeks and last traded at $9.74, 62.2% below its 52-week high. Over the past week it ranged between $9.71 and $10.63.

Past 12 Months
-7.4%
-22.7%
-58.5%
-50.8%
-36.4%
-3.1%
1W -$0.78
1M -$2.86
3M -$13.74
6M -$10.07
YTD -$5.57
1Y -$0.31

GLUE was -3.1% over the past year, -50.8% over six months, -36.4% year to date, -7.4% in the last week.

12 Months vs Market
GLUE
-3.1%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months GLUE returned -3.1% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.65× 3-mo avg
Today 885,434 3-mo avg 1.4M
1W
1.7M
1M
1.5M
3M
1.4M
6M
1.3M
YTD
1.4M
1Y
1.3M

GLUE most recently traded 885,434 shares against a 3-month average daily volume of 1.4M.

More News

Read More
News headline image
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
October 01, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
September 30, 2026
Via Chartmill
Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss ↗
August 06, 2026
Via Chartmill
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗
May 07, 2026
Via Chartmill
News headline image
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
September 30, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
September 08, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
September 01, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
August 24, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 06, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Gapping stocks in Friday's session ↗
July 31, 2026
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
July 31, 2026
Via Chartmill
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? ↗
June 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
May 20, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 07, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
April 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
April 20, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
March 17, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
March 16, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
February 24, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 9.740
When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 481.00M
How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
Monte Rosa Therapeutics, Inc. - Common Stock has 481M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap